ABEONA THERAPEUTICS INC. (ABEO)

Insider Trading Filed: 2026-04-07

Key Insights

Insider Keith A. Goldan has acquired 32,751 shares of Abeona Therapeutics Inc. (ABEO) at no cost, indicating potential confidence in the company's future.
The restricted stock acquired by Goldan will fully vest on April 1, 2027, aligning his interests with long-term shareholder value creation.
This insider transaction provides a positive signal about Abeona Therapeutics' prospects, as directors often have superior information about the company's performance and outlook.

Current Report Filed: 2026-04-07

Key Insights

Abeona Therapeutics has expanded its Board of Directors from nine to ten members, appointing Keith A. Goldan as a new independent director and Chair of the Audit Committee.
Goldan's appointment and the associated $150,000 one-time equity grant suggest the company is strengthening its leadership and governance.
The press release announcing Goldan's appointment indicates the company is proactively communicating this change to investors.

Current Report Filed: 2026-03-20

Key Insights

Abeona Therapeutics has amended its bylaws to provide more clarity around calling and conducting stockholder meetings, including allowing for virtual meetings.
The company has increased the quorum requirement for stockholder meetings from one-third to 50%, indicating a focus on ensuring robust stockholder participation.
The amendments enhance the disclosure and procedural requirements for stockholder proposals and director nominations, potentially increasing transparency.

Insider Trading Filed: 2026-01-27

Key Insights

Insider Mark Alvino acquired 37,313 shares of Abeona Therapeutics stock, which could indicate his confidence in the company's future performance.
The restricted stock awarded to Alvino will vest in one year, suggesting he is committed to the long-term success of the company.
Alvino's position as a director of Abeona Therapeutics provides him with insider knowledge, making his stock acquisition noteworthy for investors.

Insider Trading Filed: 2026-01-27

Key Insights

The reporting person, Donald A. Wuchterl, acquired 37,313 shares of Abeona Therapeutics Inc. (ABEO) common stock at $0.00, indicating a grant or award of restricted stock.
The acquired shares will vest in full on January 26, 2027, aligning the reporting person's incentives with long-term shareholder value creation.
The reporting person's total beneficial ownership in the company increased to 182,749 shares, demonstrating their continued commitment and confidence in Abeona Therapeutics.

Insider Trading Filed: 2026-01-27

Key Insights

The reporting person, Bernhardt Zeiher, was granted 37,313 restricted shares of Abeona Therapeutics Inc. (ABEO) common stock, which will vest in full on January 26, 2027.
This transaction indicates that an insider at Abeona Therapeutics is increasing their ownership stake in the company, which can be viewed positively by investors.
The reporting person now holds 84,458 shares of Abeona Therapeutics common stock, representing a significant direct ownership position in the company.

Insider Trading Filed: 2026-01-27

Key Insights

The reporting person, Eric Crombez, acquired 37,313 shares of ABEONA THERAPEUTICS INC. (ABEO) common stock at no cost, increasing his direct beneficial ownership to 79,740 shares.
The acquisition of 37,313 shares appears to be a grant of restricted stock that will vest in full on January 26, 2027, indicating potential long-term alignment between the director and company.
The transaction does not involve the purchase or sale of shares in the open market, suggesting this is part of the director's compensation package rather than an investment decision.

Insider Trading Filed: 2026-01-27

Key Insights

Christine Silverstein, a director at Abeona Therapeutics, acquired 37,313 shares of the company's common stock with no cost, indicating an alignment of interests between management and shareholders.
The vesting of the restricted stock grant will occur on January 26, 2027, suggesting a long-term commitment from the director to the company's performance and growth.
The director's ownership stake in Abeona Therapeutics has increased to 157,792 shares, demonstrating a significant and growing financial interest in the company's success.

Insider Trading Filed: 2026-01-27

Key Insights

Michael Amoroso, a director of Abeona Therapeutics Inc. (ABEO), has acquired 37,313 shares of the company's common stock at $0.00 per share, increasing his direct beneficial ownership to 217,779 shares.
The restricted stock acquired by Amoroso will vest in full on January 26, 2027, aligning his interests with those of the company and its shareholders.
Insider buying, particularly by a director, can be viewed as a positive signal and may indicate management's confidence in the company's long-term prospects.

Insider Trading Filed: 2026-01-27

Key Insights

The reporting person, Charles Faith L., acquired 37,313 shares of the issuer's common stock at no cost, increasing their direct beneficial ownership to 176,407 shares.
The shares were acquired as part of a restricted stock grant, which will fully vest on January 26, 2027, aligning the reporting person's interests with those of the company and its shareholders.
The insider transaction represents a meaningful increase in the reporting person's equity stake in the company, potentially signaling their confidence in the issuer's future prospects.

Insider Trading Filed: 2026-01-27

Key Insights

Leila Alland, a director of Abeona Therapeutics Inc. (ABEO), acquired 37,313 shares of the company's common stock at no cost, increasing her direct ownership to 191,679 shares.
The restricted stock acquired by Alland will vest in full on January 26, 2027, aligning her incentives with long-term shareholder value creation.
Insider buying, especially by directors, can be a positive signal about the company's prospects and the board's confidence in the business.

Insider Trading Filed: 2026-01-26

Key Insights

Insider Madhav Vasanthavada acquired 76,621 shares of Abeona Therapeutics Inc. (ABEO) through a restricted stock grant, increasing his direct ownership to 331,229 shares.
Vasanthavada subsequently sold 12,610 shares at a weighted average price of $5.2861 per share, likely to cover tax obligations associated with the vesting of the restricted stock.
The insider transaction suggests continued confidence in Abeona Therapeutics by a key executive, although the partial sell-off indicates a need to meet tax requirements.

Insider Trading Filed: 2026-01-22

Key Insights

The reporting person, Joseph Vazzano, the Chief Financial Officer of Abeona Therapeutics Inc., sold 18,666 shares of the company's common stock on January 22, 2026 at a weighted average price of $5.3309 per share.
The sale was to cover tax obligations associated with the vesting of restricted stock awards, indicating that the reporting person was not selling shares for personal reasons.
The reporting person still holds 568,560 shares of the company's common stock, suggesting they maintain a significant ownership position in the company.

Insider Trading Filed: 2026-01-22

Key Insights

The reporting person, Vishwas Seshadri, who is the Chief Executive Officer and a Director of Abeona Therapeutics Inc. (ABEO), sold 69,832 shares of the company's common stock on January 22, 2026 to cover tax obligations associated with the vesting of restricted stock awards.
The sale was executed at a weighted average price of $5.3309 per share, with the shares sold in multiple transactions at prices ranging from $5.33 to $5.38.
Following the reported transaction, Seshadri still holds 1,460,408 shares of the company's common stock, indicating he maintains a significant stake in the company.

Insider Trading Filed: 2026-01-22

Key Insights

Insider Brendan O'Malley, SVP and Chief Legal Officer, sold 13,578 shares of ABEONA THERAPEUTICS INC. (ABEO) at an average price of $5.33 to cover tax obligations associated with the vesting of restricted stock awards.
The reported sale of 13,578 shares represents a small portion (around 2.9%) of O'Malley's total beneficial ownership of 451,134 shares in the company.
Insider transactions can provide insights into management's views on the company's prospects, though a single transaction should be interpreted cautiously.

Insider Trading Filed: 2026-01-21

Key Insights

The Form 4 filing discloses that Mark Alvino, a director of Abeona Therapeutics, sold 13,500 shares of the company's common stock on January 21, 2026. This suggests potential insider selling activity.
The sale was conducted at a weighted average price of $5.2277 per share, which is relatively high compared to the stock's recent trading range.
The filing also indicates that Alvino continues to hold a significant position of 48,752 shares in Abeona Therapeutics following the reported transaction.

Insider Trading Filed: 2026-01-20

Key Insights

Joseph Vazzano, the Chief Financial Officer of Abeona Therapeutics Inc., has acquired 133,595 shares of the company's common stock through a stock grant that will vest over the next three years.
Vazzano's ownership in the company has increased to 587,226 shares, indicating his continued commitment to the organization.
The acquisition of the restricted stock grant suggests the company is incentivizing its key executive to remain with the firm and align their interests with those of shareholders.

Insider Trading Filed: 2026-01-20

Key Insights

Vishwas Seshadri, the CEO of Abeona Therapeutics, has acquired 365,422 shares of the company's common stock at no cost, indicating his continued commitment to the company's growth.
The restricted stock granted to the CEO will vest over the next three years, aligning his interests with those of shareholders.
The significant increase in Seshadri's direct ownership of Abeona Therapeutics' common stock suggests his confidence in the company's future prospects.

Insider Trading Filed: 2026-01-20

Key Insights

Insider Brendan O'Malley, the SVP and Chief Legal Officer, acquired 113,949 shares of Abeona Therapeutics' common stock at no cost, indicating a significant grant of restricted stock.
The restricted stock will vest over a 3-year period, suggesting a long-term incentive for O'Malley to remain with the company and contribute to its success.
This insider transaction represents a notable increase in O'Malley's direct beneficial ownership of Abeona Therapeutics' shares, which may signal his confidence in the company's future prospects.

Insider Trading Filed: 2025-12-29

Key Insights

Vishwas Seshadri, the Chief Executive Officer of Abeona Therapeutics, has sold 25,000 shares of the company's common stock at a weighted average price of $5.3096 per share.
The sale was made pursuant to a Rule 10b5-1 trading plan adopted by Seshadri in September 2024, indicating a pre-planned transaction rather than an opportunistic sale.
Seshadri still maintains a substantial stake of 1,164,818 shares, representing his continued commitment to the company.

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Important Information